Scholar Rock (NASDAQ:SRRK) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock (NASDAQ:SRRK) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans [Yahoo! Finance]
Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript [Seeking Alpha]